Navigation Links
Epigenetic control of cardiogenesis
Date:1/29/2013

This press release is available in German.

Many different tissues and organs form from pluripotent stem cells during embryonic development. To date it had been known that these processes are controlled by transcription factors for specific tissues. Scientists from the Max Planck Institute for Molecular Genetics in Berlin, in collaboration with colleagues at MIT and the Broad Institute in Boston, have now been able to demonstrate that RNA molecules, which do not act as templates for protein synthesis, participate in these processes as well. The scientists knocked down a gene for long non-coding RNA molecules (lncRNA) and thereby disrupted the development of the heart to an extent that was lethal to the embryos. Genesis of the ventral body wall was also impaired. It became apparent that the lncRNA participates in controlling transcription factors that themselves are responsible for controlling tissue- and organogenesis. The lncRNA itself thus acts as a modulating factor in these processes.

RNA molecules more than 300 nucleotides long and not exhibiting any protein-coding read frames are denoted as long non-coding RNA. They are known to interact with histone-modifying protein complexes that control the activation state of genes (activatable, active, or repressed), as well as influencing the level of their activity. This occurs, for example, through the transfer of methyl groups to histones, the DNA-packaging proteins. Modifications to the histones such as these can be copied during cell division and thus promulgate the activation state of genes from cell to cell across several stages of differentiation.

Max Planck scientists led by Bernhard Herrmann have proven for the first time that lncRNAs may also be indispensable for embryonic development. This was previously known primarily for transcription factors. They discovered an lncRNA, termed Fendrr, which is specifically formed in the progenitor cells of the heart and ventral body wall. After knocking down Fendrr in a mouse, the heart and ventral body wall were malformed, which was lethal to the embryos. The malformations first arose, however, several days after Fendrr had already been knocked down in the progenitor cells. In the case of transcription factors, the malformations appear, in contrast, after their inactivation for cells in which the gene is normally active.

This delay between the expression of the Fendrr-RNA and the appearance of the malformation can be explained by the specific effect of this new class of regulators. They influence the epigenetic control of target genes, including important transcription factors, namely by binding to histone-modifying protein complexes. Thus, they influence the fate of the descendants of cells in which they themselves were only briefly active.

The scientists now hope to locate further lncRNAs that control cardiogenesis and additional processes of embryonic development in mammals, and shed light on the mechanism of how they operate. Fendrr is probably only one of many lncRNAs that participate in epigenetic control of regulators for tissue- and organogenesis.


'/>"/>

Contact: Bernhard G. Herrmann
herrmann@molgen.mpg.de
49-308-413-1409
Max-Planck-Gesellschaft
Source:Eurekalert  

Related medicine news :

1. Astex, CRT and the Institute of Cancer Research announce epigenetic drug discovery collaboration
2. Epigenetics emerges powerfully as a clinical tool
3. New evidence for epigenetic effects of diet on healthy aging
4. Personal epigenetic signatures found consistent in prostate cancer patients metastases
5. Depo-Provera Birth Control Might Raise Breast Cancer Risk
6. Coordinating the circadian clock: Molecular pair controls time-keeping and fat metabolism
7. Certain Birth Control Pills May Carry Higher Blood Clot Risk: FDA
8. How the brains daily clock controls mood: A new project
9. Guidelines say diet, exercise, weight control improve odds after cancer diagnosis
10. Control of gene expression: Histone occupancy in your genome
11. MSU plan would control deadly tsetse fly
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Epigenetic control of cardiogenesis
(Date:1/24/2017)... ... January 23, 2017 , ... The TouchPoint Solution, ... who entered metrics into the product’s app. The data replicates and validates ... that within just 30 seconds of using Buzzies, people experienced a 74 percent ...
(Date:1/24/2017)... Michigan (PRWEB) , ... January 24, 2017 , ... The ... other advocates for drug and alcohol awareness, have worked with communities to designate the ... year, observed January 23-29, 2017, the theme is “Shatter the Myths.” As a ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... localization services for life science companies, has achieved ISO 17100:2015 certification following ... America. ISO 17100 is the globally recognized standard that establishes guidance for ...
(Date:1/23/2017)... ... 23, 2017 , ... The iaedp Foundation, recognized for its ... who treat the full spectrum of eating disorder problems, proudly announces the addition ... of the leading eating disorder treatments centers located throughout the U.S. As partners ...
(Date:1/23/2017)... ... 2017 , ... Sharon Kleyne, America’s leading water researcher, advocate and feared enemy ... of making new water infrastructure a number one priority. “As we usher in a ... infrastructure to become a top priority of our new political change agents.” Kleyne pointed ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... 23, 2017 ArisGlobal, a leading ... announces agClinical 3.3, the latest version of its comprehensive ... science organizations to confidently and efficiently meet new compliance ... the electronic trial master file so that compliance is ... ...
(Date:1/23/2017)... 2017  HOPE BIOSCIENCES announced today that it ... commercialize nuc -gemcitabine™ (APTA-12/HOPE-888) through a licensing ... nuc -Gemcitabine consists of Antisoma,s ... found on many cancer cells, and dFdCMP, an ... conjugates) or SMDCs (small molecule drug conjugates), which ...
(Date:1/23/2017)... 23, 2017  Therabron Therapeutics, Inc., a clinical-stage ... in respiratory care, today announced that the European ... has granted Orphan Drug Designation for Therabron,s CG367 ... Syndrome (BOS).  "We are pleased to ... to treat patients diagnosed with BOS following lung ...
Breaking Medicine Technology: